I believe in providing compassionate and thoughtful care for children facing cancer and various blood disorders. I strive to provide evidence-based care while understanding each patient and family as well as their perspectives which help to determine the best management for our patients. I am passionate about pediatric patients who face these disorders and will work to ensure the best possible care and outcomes for your families.
Dr. Panigrahi is a Pediatric Hematology/Oncology specialist offering care for children with various cancer diagnoses such as leukemia, lymphoma, and neuroblastoma. He also focuses his practice on various hematological conditions such as bleeding disorders (hemophilia, von Willebran disease, ITP) and clotting disorders. Finally Dr. Panigrahi leads our hemoglobinopathy program focused on sickle cell disease and thalassemia. He is involved in many clinical trials to advance care for these patients.
Dr. Panigrahi’s research focuses on various conditions such as immune thrombocytopenic purpura and on hematological malignancies such as leukemia as well as HLH. He is also interested in clinical pharmacology and advancement through clinical trials. He is also involved in many aspects of medical education for both medical students and residents.
B.S., Psychology, University of Illinois, Champaign-Urbana IL 2003
M.D., University of Massachusetts Medical School, Worcester MA 2007
Pediatrics, Tufts Medical Center, Boston MA 2007-2010
Pediatric Hematology-Oncology, University of Chicago Medical Center, Chicago IL 2010-2013
Clinical Pharmacology & Pharmacogenomics, University of Chicago Medical Center, Chicago IL 2011-2013
Sacramento Magazine List of Top Doctors, 2021, 2022
NIH T32 Post Doctoral Program in Clinical Pharmacology 2011, 2012, 2013
AAP Legislative Conference Resident Scholar, 2008
Sabet K, Panigrahi A, Chung J, Dayan Y. Pediatric AML patients with acute-onset cardiomyopathy in the setting of Streptococcus viridans bacteremia after anthracyclines. Pediatr Blood Cancer. 2022 Feb;69(2):e29450. doi:10.1002/pbc.29450. Epub 2021 Dec 2. PMID:34854543.
Goldenberg N., Kittelson J., Abshire T., et al, Kids-DOTT Trial Investigators (Panigrahi AR). Effect of Anticoagulant Therapy for 6 weeks vs. 3 Months on Recurrence and Bleeding Evens in Patients Younger than 21 Years of Age With Provoked Venous Thromboembolism. JAMA. 2022 Jan 11. doi:10.1001/jama.2021.23182.
Vlachos A, Atsidaftos E, Lababidi ML, Muir E, Rogers ZR, Alhushki W, Bernstein J, Glader B, Gruner B, Hartung H, Knoll C, Loew T, Nalepa G, Narla A, Panigrahi AR, Sieff CA, Walkovich K, Farrar JE, Lipton JM. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatr Blood Cancer. 2020 Dec;67(12):e28748. doi:10.1002/pbc.28748. Epub 2020 Oct 6. PMID:33025707.
Nessle CN, Ghosal S, Mathews C, Taylor D, Myers J, Raj A, Panigrahi A. Weak correlation of bleeding scores to platelet electron microscopy: A retrospective chart review of pediatric patients with delta-storage pool disorder. Pediatr Blood Cancer. 2019 Mar;66(3):e27505. doi:10.1002/pbc.27505. Epub 2018 Oct 21. PMID:30345617.
Spiwak E, Wiesenauer C, Panigrahi A, Raj A. Use of Pleuroperitoneal Shunt in Chylothorax Related to Central Line Associated Thrombosis in Sickle Cell Disease. Children (Basel). 2018 Jan 2;5(1):7. doi:10.3390/children5010007. PMID:29301288.
Panigrahi A, Clark A, Myers J, Raj A. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias. Pediatr Blood Cancer. 2017 Feb;64(2):287-293. doi:10.1002/pbc.26210. Epub 2016 Sep 12. PMID:27615037.
Myers SN, Eid R, Myers J, Bertolone S, Panigrahi A, Mullinax J, Raj AB. Long-term Erythrocytapheresis Is Associated With Reduced Liver Iron Concentration in Sickle Cell Disease. J Pediatr Hematol Oncol. 2016 Jan;38(1):22-6. doi:10.1097/MPH.0000000000000461. PMID:26650249.
Madian AG, Panigrahi A, Perera MA, Pinto N. Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. BMC Pharmacol Toxicol. 2014 Dec 3;15:69. doi:10.1186/2050-6511-15-69. PMID:25472557.
Panigrahi AR, Ratichek SJ, Recklitis C, Chang G, Tighiouart H, Terrin N, Parsons SK. Interrater Comparisons of Children's Health-Related Quality of Life(HRQL) during the Acute Peri-Transplant Period. Pediatric Blood & Cancer. 2009 Jun;52(6):702.